Skip to main content
. 2017 Jul 5;8(32):53631–53641. doi: 10.18632/oncotarget.19022

Figure 3. Overall response outcomes for cetuximab by primary tumor location in patients with metastatic colorectal cancer (forest plot of the hazard ratio for pooled overall response in patients with LCRC vs. RCC; LCRC, left-sided colorectal cancer; RCC, right-sided colorectal cancer).

Figure 3